NCT02254915撤回3 期
A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)
Medical Enterprises Europe B.V.0 个研究点开始时间: 2014年10月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 主要终点
- RFS time
研究概览
简要总结
A multi-institutional, prospective, randomised, open-label, superiority, comparative, active-controlled, phase 3 study. The study will compare Synergo RF-induced hyperthermia-chemotherapy (SHTC) plus mitomycin C (MMC) to standard treatment of bacillus Calmette-Guérin (BCG) therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC, and will evaluate recurrence and progression rate over two years of follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary intermediate or high-risk papillary NMIBC according to the EAU Guidelines and intermediate and high-risk recurrences that have not received BCG within the previous 2 years or chemotherapy treatment (apart from one early instillation) within the previous year.
- •All clinical, intra-operative and pathological items for the EAU risk stratification must be documented including a bladder map.
- •Patients must have undergone a re-resection (second TURB in accordance with the EAU Guidelines) (i) if the initial TURB was incomplete (ii) if there was no muscle in the specimen after the initial TURB (except in TaG1/LG tumours) (iii) in all T1 and all G3/HG tumours TURB of T1 sites must include muscle. Re-resection must be negative in patients diagnosed with T1 and/or G3/HG and/or multiple tumours in the initial TURB.
- •No UC in the upper tract, kidney and ureters. This should be confirmed by CT-IVU or IVU performed at time of initial diagnosis in selected cases as recommended in latest EAU guidelines published prior to screening.
- •No UC in the urethra, excluded by visual inspection during cystoscopy and, in addition, in patients with (i) tumour of trigone (ii) tumour of bladder neck (iii) abnormal prostatic urethra UC must be excluded by biopsy of the prostatic urethra in all male patients or, in female patients, from the portion of the urethra adjacent to the bladder neck, before study recruitment.
- •All patients must have urine cytology dated within the screening period prior to randomisation.
- •Age ≥ 18 yrs
- •Normal kidneys and ureters.
- •Pre-treatment haematology and biochemistry values within acceptable limits:
- •(i) haemoglobin ≥ 10 g/dl (g/100 ml) (ii) platelets ≥ 150 x 109/L (103/mm3) (iii) WBC ≥ 3.0 x 109/L (103/mm3) (iv) ANC ≥ 1.5 x 109/L (103/mm3, absolute neutrophil count) (v) Serum creatinine, SGOT, SGPT, Alkaline phosphatase: < 1.5 x UNL (upper normal limit)
- •Negative pregnancy test for women of child-bearing potential
- •A life expectancy at least of the duration of the trial.
- •Unfit or unwilling to have a full or partial cystectomy.
- •Signed informed consent.
排除标准
- •UC involving the prostatic urethra
- •Non-UC tumour of the urinary tract
- •Upper tract and intramural tumours (e.g. in Ostium).
- •History of stage > T1 UC.
- •CIS (suspected or present).
- •Known or suspected reduced bladder capacity. Patients will have a US estimation of maximum bladder capacity or void spontaneously the maximum they can retain in their bladder, and this will be used to determine urine volume. A minimum volume of 250 ml is required.
- •Bleeding disorder
- •Macrohaematuria of ≥ 250 RBC's/uL or equivalent (e.g. > "+++" erythrocytes in a dipstick analysis).
- •Pregnant or lactating women.
- •Women of childbearing potential unwilling or unable to use adequate contraception if sexually active.
- •More than a maintenance dose of oral corticosteroids (maintenance dose defined as the same dose regimen over the past 6 months for a condition requiring continual corticosteroid treatment) or patients with an immuno-compromised state for any reason.
- •More than low-dose Methotrexate (>17.5 mg once a week).
- •Other malignancy within the past five years, except: non-melanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix or ductal CIS (DCIS)/lobular CIS (LCIS) of the breast or stable prostate cancer (under active surveillance or hormone control) with a life expectancy of more than 5 years.
- •Any known allergy or adverse event that would prevent them from receiving a treatment that they may be randomised to within the trial.
- •Known untreated strictural disease or bladder neck contracture or any other condition that may prevent catheterisation with 21F catheter. Patients may undergo dilation or urethral incision before entering the study.
- •Bladder diverticula with cumulative diameter > 1cm
- •UTI at any time within 6 months preceding randomisation.
- •Significant urinary incontinence (spontaneous, requiring use of pads)
- •History of pelvic irradiation
- •Patients with implanted electronic devices (such as cardiac pacemakers) unless they receive permission from their treating physician (e.g., cardiologist) and are monitored by a treating physician during the treatment session.
- •Participation in another study which includes treatment that is liable to have an effect on this study.
研究组 & 干预措施
Synergo + MMC
Experimental
Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
干预措施: Synergo + MMC (Device)
Bacillus Calmette-Guérin
Active Comparator
Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
干预措施: Bacillus Calmette-Guérin (Drug)
结局指标
主要结局
RFS time
时间窗: 2 years
The recurrence-free survival time in patients with NMIBC following treatment with SHTC (investigational arm) compared to BCG (controlled arm).
次要结局
- Treatment discontinuation(2 years)
- Progression-free survival time(2 years)
- Adverse events(2 years)
- Recurrence free survival time by risk group(2 years)
- Overall survival time(2 years)
- Organ preservation rate(2 years)
- Disease-specific survival time(2 years)
研究者
相似试验
已完成
3 期
Comparative Study of BAY86-5300 With a Flexible Extended Regimen for DysmenorrheaDysmenorrheaNCT01892904Bayer216
进行中（未招募）
1 期
A multicentre, randomised, open-label, active-controlled trial of the effectiveness of buprenorphine/naloxone in reducing intravenous buprenorphine misuse in France - RIME StudyFor both compounds, substitution treatment for opioid drug dependence, adult subjects with a diagnosis of major heroin dependence. Only for Suboxone, the intention of naloxone is to deter the intravenous misuse.MedDRA version: 9.1Level: LLTClassification code 10012346Term: Dependence on opiatesEUCTR2009-010360-41-FRReckitt Benckiser Healthcare (UK) Limited270
招募中
3 期
Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRelapsed Small Cell Lung CancerNCT06128837Luye Pharma Group Ltd.686
尚未招募
不适用
Onderzoek naar het voorkómen van nierfalen na levertransplantatie door aanpassing van de afweerremmende middelen.NL-OMON26731Foundation for Liver and Gastrointestinal Research (SLO)Department of Gastroenterology & HepatologyErasmus Medical Center Rotterdam‘s Gravendijkwal 230, Room HA 2043015 CE Rotterdam, The NetherlandsTel: +31 10 703 5942 Fax: +31 10 436 5916196
Unknown
不适用
Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.Coronary Artery DiseaseNCT03721614Meril Life Sciences Pvt. Ltd.200